Clinical Trial Update: Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL [NA]

View source ↗

Summary

This clinical trial is evaluating a combination of teniposide, a PD-1 monoclonal antibody, and selinixor for relapsed or refractory primary central nervous syst…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• PD-1 monoclonal antibody
• Selinixor (selinixor)
• Teniposide (teniposide)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Primary Central Nervous System Lymphoma (PCNSL) | NA | Status: RECRUITING